175 related articles for article (PubMed ID: 29475590)
1. Validation of Iodine-131-meta-iodobenzylguanidine cardiac scintigraphy in Parkinsonism: A preliminary study.
Xu D; Zhu W; Huo L; Zhu S; Li F; Wang H
Parkinsonism Relat Disord; 2018 May; 50():69-73. PubMed ID: 29475590
[TBL] [Abstract][Full Text] [Related]
2. MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy.
Chung EJ; Lee WY; Yoon WT; Kim BJ; Lee GH
Mov Disord; 2009 Aug; 24(11):1650-5. PubMed ID: 19514077
[TBL] [Abstract][Full Text] [Related]
3. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy].
Yoshita M; Hayashi M; Hirai S
Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173
[TBL] [Abstract][Full Text] [Related]
4. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis.
Orimo S; Suzuki M; Inaba A; Mizusawa H
Parkinsonism Relat Disord; 2012 Jun; 18(5):494-500. PubMed ID: 22321865
[TBL] [Abstract][Full Text] [Related]
5.
Yang T; Wang L; Li Y; Cheng M; Jiao J; Wang Q; Guo H
J Neurol Sci; 2017 Feb; 373():48-51. PubMed ID: 28131225
[TBL] [Abstract][Full Text] [Related]
6. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. taki@med.kanazawa-u.ac.jp.
Taki J; Nakajima K; Hwang EH; Matsunari I; Komai K; Yoshita M; Sakajiri K; Tonami N
Eur J Nucl Med; 2000 May; 27(5):566-73. PubMed ID: 10853813
[TBL] [Abstract][Full Text] [Related]
7. Initial Versus Follow-up Sequential Myocardial 123I-MIBG Scintigraphy to Discriminate Parkinson Disease From Atypical Parkinsonian Syndromes.
Ryu DW; Kim JS; Lee JE; Oh YS; Yoo SW; Yoo IR; Lee KS
Clin Nucl Med; 2019 Apr; 44(4):282-288. PubMed ID: 30589669
[TBL] [Abstract][Full Text] [Related]
8. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.
Uyama N; Otsuka H; Shinya T; Otomi Y; Harada M; Sako W; Izumi Y; Kaji R; Watanabe Y; Takashi S; Kunikane Y
Nucl Med Commun; 2017 Jun; 38(6):487-492. PubMed ID: 28410288
[TBL] [Abstract][Full Text] [Related]
9. MIBG myocardial scintigraphy in progressive supranuclear palsy.
Kamada T; Miura S; Kida H; Irie KI; Yamanishi Y; Hoshino T; Taniwaki T
J Neurol Sci; 2019 Jan; 396():3-7. PubMed ID: 30391822
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity and specificity of cardiac
Kawazoe M; Arima H; Maeda T; Tsuji M; Mishima T; Fujioka S; Tsugawa J; Tsuboi Y
J Neurol Sci; 2019 Dec; 407():116409. PubMed ID: 31706063
[TBL] [Abstract][Full Text] [Related]
11. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.
Orimo S; Ozawa E; Nakade S; Sugimoto T; Mizusawa H
J Neurol Neurosurg Psychiatry; 1999 Aug; 67(2):189-94. PubMed ID: 10406987
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes.
Fujita H; Suzuki K; Numao A; Watanabe Y; Uchiyama T; Miyamoto T; Miyamoto M; Hirata K
PLoS One; 2016; 11(11):e0165869. PubMed ID: 27812167
[TBL] [Abstract][Full Text] [Related]
13. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis.
Treglia G; Cason E; Stefanelli A; Cocciolillo F; Di Giuda D; Fagioli G; Giordano A
Clin Auton Res; 2012 Feb; 22(1):43-55. PubMed ID: 21792729
[TBL] [Abstract][Full Text] [Related]
14. [Cardiac sympathetic dysfunction in Parkinson's disease--relationship between results of 123I-MIBG scintigraphy and autonomic nervous function evaluated by the Valsalva maneuver].
Oka H; Yoshioka M; Morita M; Mochio S; Inoue K
Rinsho Shinkeigaku; 2003 Aug; 43(8):465-9. PubMed ID: 14658397
[TBL] [Abstract][Full Text] [Related]
15. [
Nuvoli S; Spanu A; Fravolini ML; Bianconi F; Cascianelli S; Madeddu G; Palumbo B
Mol Imaging Biol; 2020 Jun; 22(3):703-710. PubMed ID: 31309370
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of parkinsonian patients exhibiting normal (123)I-MIBG cardiac uptake.
Mizutani Y; Ito S; Murate K; Hirota S; Fukui T; Hikichi C; Ishikawa T; Shima S; Ueda A; Kizawa M; Asakura K; Mutoh T
J Neurol Sci; 2015 Dec; 359(1-2):236-40. PubMed ID: 26671120
[TBL] [Abstract][Full Text] [Related]
17. Correlation with sympathetic skin response,
Ozawa M; Morishima R; Shimizu T; Takahashi K
Neurophysiol Clin; 2024 Jul; 54(4):102956. PubMed ID: 38422587
[TBL] [Abstract][Full Text] [Related]
18. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
[TBL] [Abstract][Full Text] [Related]
19. Differentiating Parkinson's disease from multiple system atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test.
Kikuchi A; Baba T; Hasegawa T; Sugeno N; Konno M; Takeda A
Parkinsonism Relat Disord; 2011 Nov; 17(9):698-700. PubMed ID: 21840242
[TBL] [Abstract][Full Text] [Related]
20. Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure.
Veltman CE; Boogers MJ; Meinardi JE; Al Younis I; Dibbets-Schneider P; Van der Wall EE; Bax JJ; Scholte AJ
Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1599-608. PubMed ID: 22790878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
